Kidney Cancer Weekly

May 18, 2026

Videos

Peer-to-Peer Clinical Conversations

LITESPARK-024: Belzutifan Plus Palbociclib in Advanced Clear Cell RCC - David McDermott

David McDermott

David McDermott discusses LITESPARK-024, a study combining belzutifan with palbociclib in clear cell RCC based on preclinical evidence of synthetic lethality between VHL mutation and CDK4/6 inhibition.

Phase I Trial Explores Formulation of CBM588 Probiotic in Advanced RCC - Miguel Zugman

Miguel Zugman presents phase I dose escalation results testing refrigerated capsule formulation of CBM588 probiotic with nivolumab/ipilimumab in 12 first-line metastatic clear cell renal cell carcinoma patients.

Beyond the Abstracts

Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use - Beyond the Abstract

Real-World Evidence of Nivolumab Monotherapy in Advanced Renal Cell Carcinoma from a Multicenter Retrospective Cohort Study by the Spanish Genitourinary Oncology Group - Beyond the Abstract

Conference Coverage

AUA 2026: State-of-the-Art Lecture: The Emerging Role of Focal Therapy in Renal Cell Carcinoma

SES AUA 2026: Impact of Cytoreductive Nephrectomy for RCC with Tumor Thrombus: Results from the Intercontinental Collaboration of RCC

EAU 2026: Society of Urologic Oncology (SUO) Lecture: Rare Renal Tumors: What Should the General Urologist Know?

ASCO GU 2026: Discussant: Prevention to Progression – Targeting Foundational Biology in RCC

ASCO GU 2026: Response of Venous Tumor Thrombi in RCC to Immune Checkpoint Inhibitor Therapy: A Multicenter Retrospective Cohort Study

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial.

Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma.

C-Reactive Protein/Albumin Ratio (CAR)-Integrated IMDC Model Improves Risk Stratification in Metastatic Renal Cell Carcinoma.

Nephron Sparing Treatment (NEST) for small renal masses: understanding patients' and clinicians' experiences of a cohort-embedded randomised control trial.

Kidney Cancer Trends, Risk Factors, and Interventions in American Indian and Alaska Native Populations: The Kidney Cancer Association Scientific Statement.

Diagnostic Role and Clinical Impact of Zr-Girentuximab PET-CT for the Diagnosis and Treatment of Clear-Cell Renal Cell Carcinoma.

Clinical profile and management outcomes of small renal masses: a collaborative multi-institutional Indian study led by the society of genitourinary oncologists.

Hong Kong Urological Association-Hong Kong Society of Uro-Oncology 2025 consensus on the management of locally advanced or metastatic renal cell carcinoma.

PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma.

Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study.

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC